Search clinical trials for: Inhibition

Total 3244 results

LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

Acute Coronary Syndrome

China
The University of Texas Health Science Center at...
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Thrombocythemia, Essential

United States
Northwestern University
National Cancer Institute (NCI); Bayer

Completed

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Angiosarcoma

United States
National Cancer Institute (NCI)

Completed

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Stage IV Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder...

United States
National Cancer Institute (NCI)

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Melanoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Renal Cancer | Hepatocarcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
University of Wisconsin, Madison

Completed

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

Cardiovascular Disease | Chronic Kidney Disease

United States
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
Jennifer Woyach
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
CSL Behring

Completed

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Erin Bertino
Karyopharm Therapeutics Inc

Terminated

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Recurrent Small Cell Lung Carcinoma

United States
Pharming Technologies B.V.
University of Wisconsin, Madison

Withdrawn

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

Kidney Transplantation | Graft Rejection

United States
Tesaro, Inc.

Completed

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United Kingdom, United States, Taiwan, Spain, Poland
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
Jeil Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

Korea, Republic of
Tianjin Medical University Cancer Institute and...

Recruiting

PD1 and PARP for Maintenance Therapy in NSLLC

Lung Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Estrogen Receptor and/or Progesterone Receptor Positive

United States
Kiora Pharmaceuticals, Inc.

Terminated

A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease

Dry Eye Disease

Australia
Mayo Clinic
National Cancer Institute (NCI)

Completed

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin Lymphoma

United States
Jason Robert Gotlib
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Systemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic Mastocytosis

United States
National Cancer Institute (NCI)

Terminated

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma

United States
Nestlé
Institut National de la Recherche Agronomique; Centre de Recherche en Nutrition...

Completed

Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women

Osteoporosis, Osteopenia

France
Merck Sharp & Dohme LLC

Completed

Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)

Neoplasms
NewAmsterdam Pharma

Completed

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (ROSE)

Dyslipidemias | Hypercholesterolemia | High Cholesterol

United States
SecuraBio

Completed

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Asthma

Germany, United Kingdom
National Cancer Institute (NCI)

Completed

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia

Lip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Oral Leukoplakia

United States
Pfizer

Completed

A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers

Chronic Pain | Acute Pain

Singapore
Lisa Barrett
Nova Scotia Health Authority; Dalhousie University

Active, not recruiting

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

COVID-19

Canada
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Medical University of Lodz

Completed

Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia (PULSAR)

Schizophrenia

Poland
Panineeya Mahavidyalaya Institute of Dental Sciences...

Completed

The Association of SERPINA1 Gene Disturbance in Patients With Lung and Gum Disorders (SA1PLG)

Pulmonary Disease, Chronic Obstructive | Generalized Chronic Periodontitis

India
Pfizer

Completed

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Australia
Cliniques universitaires Saint-Luc- Université...

Terminated

Peptide Vaccinations Plus GM-CT-01 in Melanoma

Metastatic Melanoma

Belgium
Pharming Technologies B.V.

Completed

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (OPERA)

Hereditary Angioedema | Genetic Disorders

Netherlands, Romania
Manmeet Ahluwalia, MD
National Cancer Institute (NCI); Novartis

Completed

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
Azienda Ospedaliera Universitaria Policlinico "G...
Gianluca Di Bella; Antonio Micari; Giampiero Vizzari; Giorgio Quadri; Greca Zanda; Ferdinando...

Recruiting

De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS (DESC-HBR)

Coronary Artery Disease | Acute Coronary Syndrome | Dual Antiplatelet Therapy

Italy
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Advanced HR+ HER2 Negative Breast Carcinoma
Aveni Foundation

Withdrawn

CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 (CORONA)

COVID-19 | Acute Respiratory Distress Syndrome | Cytokine Storm
Kiminori Kimura, MD
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.; National... and other collaborators

Completed

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Hepatitis B | Hepatitis C | Liver Cirrhoses

Japan
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
Anne Chang
Novartis Pharmaceuticals

Terminated

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Carcinoma, Basal Cell | Skin Neoplasms | Basal Cell Nevus Syndrome | Recurrent Skin Cancer

United States
Newron Pharmaceuticals SPA

Terminated

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) (MOTION)

Idiopathic Parkinson's Disease

Switzerland

Search clinical trials for: Inhibition

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations